Evercore ISI added Exact Sciences (EXAS) to the firm’s “Tactical Outperform List” while keeping an Outperform rating on the shares with a $72 price target. The stock has a “multiple catalysts lining up,” with Exact presenting its algorithm setting data for its blood based test on Monday, September 16. The firm expects to see a colorectal cancer sensitivity inline with Guardant Health’s (GH) 83% and advanced adenoma sensitivity potentially a tad better. Evercore believes the algorithm setting data will be a good proxy for Exact’s pivotal BLUE-C blood results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz
- Illumina upgraded, Fiserv initiated: Wall Street’s top analyst calls
- Wells Fargo starts tools and diagnostics group with positive bias
- Exact Sciences initiated with an Overweight at Wells Fargo
- Exact Sciences: 1st patient enrolled in MCED Falcon Registry RWE study